TY - JOUR
T1 - Combined inhalation of beta2 -agonists improves swim ergometer sprint performance but not high-intensity swim performance
AU - Kalsen, Anders
AU - Hostrup, Morten
AU - Bangsbo, Jens
AU - Backer, Vibeke
N1 - CURIS 2014 NEXS 280
PY - 2014/10/1
Y1 - 2014/10/1
N2 - There is a high prevalence of asthma and airway hyperresponsiveness (AHR) in elite athletes, which leads to a major use of beta2-agonists. In a randomized double-blinded crossover study, we investigated the effects of combined inhalation of beta2-agonists (salbutamol, formoterol, and salmeterol), in permitted doses within the World Anti-Doping Agency 2013 prohibited list, in elite swimmers with (AHR, n=13) or without (non-AHR, n=17) AHR. Maximal voluntary isometric contraction of m. quadriceps (MVC), sprint performance on a swim ergometer and performance in an exhaustive swim test at 110% of VO2max were determined. Venous plasma interleukin-6 (IL-6) and interleukin-8 (IL-8) were measured post-exercise. No improvement was observed in the exhaustive swim test, but swim ergometer sprint time was improved (P<0.05) in both groups from 57±1.7 to 56±1.8s in AHR and 58.3±1 to 57.4±1s in non-AHR. MVC and post-exercise plasma IL-6 increased (P<0.05) with beta2-agonists in both groups, whereas IL-8 only increased in AHR. In summary, inhalation of beta2-agonists, in permitted doses, did not improve swim performance in elite swimmers. However, swim ergometer sprint performance and MVC were increased, which should be considered when making future anti-doping regulations.
AB - There is a high prevalence of asthma and airway hyperresponsiveness (AHR) in elite athletes, which leads to a major use of beta2-agonists. In a randomized double-blinded crossover study, we investigated the effects of combined inhalation of beta2-agonists (salbutamol, formoterol, and salmeterol), in permitted doses within the World Anti-Doping Agency 2013 prohibited list, in elite swimmers with (AHR, n=13) or without (non-AHR, n=17) AHR. Maximal voluntary isometric contraction of m. quadriceps (MVC), sprint performance on a swim ergometer and performance in an exhaustive swim test at 110% of VO2max were determined. Venous plasma interleukin-6 (IL-6) and interleukin-8 (IL-8) were measured post-exercise. No improvement was observed in the exhaustive swim test, but swim ergometer sprint time was improved (P<0.05) in both groups from 57±1.7 to 56±1.8s in AHR and 58.3±1 to 57.4±1s in non-AHR. MVC and post-exercise plasma IL-6 increased (P<0.05) with beta2-agonists in both groups, whereas IL-8 only increased in AHR. In summary, inhalation of beta2-agonists, in permitted doses, did not improve swim performance in elite swimmers. However, swim ergometer sprint performance and MVC were increased, which should be considered when making future anti-doping regulations.
U2 - 10.1111/sms.12096
DO - 10.1111/sms.12096
M3 - Journal article
C2 - 23834392
SN - 0905-7188
VL - 24
SP - 814
EP - 822
JO - Scandinavian Journal of Medicine & Science in Sports
JF - Scandinavian Journal of Medicine & Science in Sports
IS - 5
ER -